![]() |
市場調查報告書
商品編碼
1697828
高內涵篩檢市場:全球按產品/服務、應用、最終用戶和地區分類 - 預測至 2030 年High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030 |
全球高內涵篩檢市場規模預計將從 2025 年的 15.2 億美元成長到 2030 年的 21.9 億美元,複合年成長率高達 7.5%。
由於高解析度成像、自動化和人工智慧 (AI) 驅動的資料分析的創新顯著提高了 HCS 工作流程的效率和準確性,市場正在以顯著的複合年成長率成長。具有高速螢光顯微鏡、共聚焦成像和即時活細胞分析功能的先進儀器可以更深入地了解細胞,對於藥物發現、毒性篩檢和疾病研究至關重要。
研究範圍 | |
---|---|
調查年份 | 2023-2030 |
基準年 | 2024 |
預測期 | 2025-2030 |
對價單位 | 金額(美元) |
按細分市場 | 按產品/服務、按應用、按最終用戶、按地區 |
目標區域 | 北美、歐洲、亞太地區、拉丁美洲、中東和非洲 |
根據產品/服務,高內涵篩檢市場可細分為儀器、消耗品/配件、軟體和服務。儀器部分進一步分為高內涵成像平台、細胞檢測和分析系統以及細胞成像系統。製藥和生物技術研究中對高通量篩檢和多重分析的需求不斷成長,加速了下一代 HCS 系統的採用。隨著研究機構和商業實驗室致力於提高生產力和效率,對尖端 HCS 設備的需求預計將推動市場大幅成長。
應用部分分為藥物發現和開發、毒理學和基礎研究。藥物發現和開發應用可進一步分為篩檢篩檢和二次篩選、標靶識別和驗證、化合物分析以及其他藥物發現和開發應用。藥物發現和開發佔據了市場主導地位,因為人工智慧和自動化在藥物發現工作流程中的整合進一步提高了HCS的效率,減少了與臨床前研究相關的時間和成本。此外,監管機構非常重視早期毒性評估,使得HCS成為臨床試驗前藥物安全性評估的首選工具。由於這些因素的綜合作用,藥物發現和開發應用佔據了HCS市場的絕大部分佔有率。
根據最終用戶,市場細分為製藥和生物技術公司、學術和政府組織以及 CRO 和 CDMO。到 2024 年,製藥和生物技術公司將主導這一領域。製藥和生物技術公司在高內涵篩檢(HCS) 市場中的高佔有率主要是由於 HCS 技術在藥物發現和市場開發中的廣泛應用。這些公司利用HCS進行高通量篩檢、先導化合物最佳化和毒性評估,以加速藥物開發過程,同時確保安全性和有效性。
市場依地區分為北美、歐洲、亞太、拉丁美洲及中東及非洲。 2024 年,北美佔據了高內涵篩檢市場的主導地位,預計在預測期內將繼續佔據主導地位。美國憑藉其主要學術研究機構和對生物技術的大量投資引領北美市場。該國對創新醫學研究、個人化醫療保健和精準醫療的關注進一步鞏固了其在市場上的領先地位。歐洲高內涵篩檢市場正在穩步成長,這得益於不斷增加的研發活動,尤其是在德國、英國和法國等國家。
本報告研究了全球高內涵篩檢市場,並對市場按產品/服務、應用、最終用戶和地理趨勢進行了詳細分析,並提供了參與市場的公司概況。
The global high content screening market is anticipated to reach USD 2.19 billion in 2030 from USD 1.52 billion in 2025, with a significant CAGR of 7.5%. The market is growing at a significant CAGR owing to the innovations in high-resolution imaging, automation, and artificial intelligence (AI)-powered data analysis, which have significantly enhanced the efficiency and accuracy of HCS workflows. Advanced instruments equipped with high-speed fluorescence microscopy, confocal imaging, and real-time live-cell analysis enable deeper cellular insights, making them essential for drug discovery, toxicity screening, and disease research.
Scope of the Report | |
---|---|
Years Considered for the Study | 2023-2030 |
Base Year | 2024 |
Forecast Period | 2025-2030 |
Units Considered | Value (USD) |
Segments | By Products & Service, Application and End User |
Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"Instruments dominated the products & service segment"
Based on product & service, the high content screening market is divided into instruments, consumables & accessories, software, and services. The instrument segment is further divided into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The rising demand for high-throughput screening and multiplexed assays in pharmaceutical and biotechnology research has accelerated the adoption of next-generation HCS systems. As research institutions and commercial laboratories seek to improve productivity and efficiency, the demand for cutting-edge HCS instruments is expected to drive significant market growth.
"Drug discovery & development application segment is anticipated to grow at a great pace"
The application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications. The drug discovery & development dominated the market owing to the integration of artificial intelligence and automation in drug discovery workflows further enhances the efficiency of HCS, reducing time and costs associated with preclinical research. Furthermore, regulatory bodies emphasize early toxicity assessment, making HCS a preferred choice for evaluating drug safety before clinical trials. These factors collectively contribute to the dominant market share of drug discovery and development applications in the HCS market.
"Pharmaceutical & Biotechnology Companies dominated the segment"
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. Pharmaceutical & biotechnology companies dominated the segment in 2024. The high share of pharmaceutical and biotechnology companies in the high content screening (HCS) market is primarily driven by their extensive use of HCS technologies in drug discovery and development. These companies rely on HCS for high-throughput screening, lead optimization, and toxicity assessment to accelerate the drug development process while ensuring safety and efficacy.
"North America: the largest share of the high content screening market"
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the high content screening market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The country's focus on innovative medical research, personalized healthcare, and precision medicine further boosts its leadership in the market. European high content screening market is experiencing steady growth, supported by increasing research and development activities, especially in countries like Germany, the UK, and France.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the high content screening market.
The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Corning Incorporated (US), Bio-Rad Laboratories Inc (US), Tecan Trading AG (Switzerland), Evident (Japan), Sysmex Corporation (Japan), Yokogawa Electric Corporation (Japan), Nikon Corporation (Japan), Sartorius AG (Germany), Promega Corporation (US), Creative Biolabs (US), Enzo Life Sciences (US), Stratedigm Inc. (US), Akoya Biosciences, Inc. (US), Sphere Fluidics (UK), Creative Biostructure (US), Creative Bioarray (US), Cell Signalling Technology (US), Standard Biotools (US), Araceli Biosciences (US), and among others.
High content screening market report is segmented based on products & services (instruments (high content imaging platforms, cell detection and analysis systems, and cell imaging systems), consumables & accessories (reagents & assay kits, microplates, and other consumables accessories), software, and services. Applications (drug discovery & development applications (primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications), toxicology, and basic research, end users (pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the high content screening and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.